{
    "clinical_study": {
        "@rank": "72366", 
        "arm_group": {
            "arm_group_label": "chlorogenic acid", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to explore if chlorogenic acid is safe in patients with cancer."
        }, 
        "brief_title": "Phase 1 Trial of Chlorogenic Acid in Patients With Advanced Cancer", 
        "condition": "Advanced Cancer", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  advanced cancer with no effective treatment\n\n          -  Karnofsky performance status no less than 70\n\n          -  adequated organ function\n\n          -  informed consent\n\n        Exclusion Criteria:\n\n          -  allergic to chlorogenic acid\n\n          -  persistent toxicities from previous treatment (no less than grade 2)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "May 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02136342", 
            "org_study_id": "LYS-I-01"
        }, 
        "intervention": {
            "arm_group_label": "chlorogenic acid", 
            "intervention_name": "chlorogenic acid", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "no available effective treatment", 
        "lastchanged_date": "May 12, 2014", 
        "number_of_arms": "1", 
        "official_title": "Phase 1 Trial Evaluating Tolerability and Pharmacokinetics of Chlorogenic Acid for Injection in Patients With Advanced Cancer", 
        "other_outcome": [
            {
                "measure": "Change in number of red blood cell and level of hemoglobin", 
                "safety_issue": "No", 
                "time_frame": "within 1 year after the first dose of chlorogenic acid"
            }, 
            {
                "measure": "change in the diameters of lymph node metastasis", 
                "safety_issue": "No", 
                "time_frame": "within 1 year after the first dose of chlorogenic acid"
            }, 
            {
                "measure": "change in levels of tumor markers", 
                "safety_issue": "No", 
                "time_frame": "within 1 year after the first dose of chlorogenic acid"
            }
        ], 
        "overall_contact": {
            "email": "medart@yeah.net", 
            "last_name": "Sheng Yang, Dr.", 
            "phone": "86-10-87788532"
        }, 
        "overall_contact_backup": {
            "last_name": "Yutao Liu, Dr.", 
            "phone": "86-10-87788119"
        }, 
        "overall_official": {
            "affiliation": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences", 
            "last_name": "Yuankai Shi, Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "within the first 60 days after the first dose of chlorogenic acid"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02136342"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese Academy of Medical Sciences", 
            "investigator_full_name": "Shi Yuankai", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "dose-limiting toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "within the first 30 days after the first dose of chlorogenic acid"
            }, 
            {
                "measure": "maximum tolerated dose", 
                "safety_issue": "Yes", 
                "time_frame": "within the first 30 days after the first dose of chlorogenic acid"
            }, 
            {
                "measure": "Area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax) of  chlorogenic acid", 
                "safety_issue": "No", 
                "time_frame": "within the first 30 days after the first dose of chlorogenic acid"
            }, 
            {
                "measure": "improvement in cancer-related symptoms and quality of life", 
                "safety_issue": "No", 
                "time_frame": "within 1 year after the first dose of chlorogenic acid"
            }
        ], 
        "source": "Chinese Academy of Medical Sciences", 
        "sponsors": {
            "collaborator": {
                "agency": "Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Chinese Academy of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}